| Name | Title | Contact Details |
|---|
Rapid Enrollment Solutions is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LakeWood Health Center consists of the following four divisions: care center, clinic, hospital, and public health.. They service a population of 6,000 to 9,000 people, the number fluctuating with seasonal tourism activities. LakeWood is a federally designated Critical Access Hospital. As a Catholic non-profit organization, LakeWood Health Center is located in Baudette, Minnesota, and is owned and operated by Catholic Health Initiatives of Denver, Colorado. Our staff serve the social, health and welfare needs of the residents in Lake of the Woods County; contiguous counties, Koochiching, Beltrami, and Roseau; and neighboring Canada.
RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.
We connect world class science to consumer health. We use science and math to enable average consumers to understand their health risk relative to their peers (age & gender) based on their behaviors. We enable organizations to develop affinity with their members, employees, patients and customers by facilitating consumer-driven, personalized user experiences. We do the heavy lifting and provide you with the data. We facilitate a permanent relationship with consumers, providing value as an entry point to preventative self-directed healthcare.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.